Foresite Capital

🚨 Breaking News 🚨 Pivotal new research in pregnancy health was presented today by Dr. Kara Rood of The Ohio State University Wexner Medical Center at The Society for Maternal-Fetal Medicine’s (#SMFM25) annual meeting, highlighting how Mirvie used RNA to uncover which babies are most at-risk for severe fetal growth restriction🔬💡🧬 There is a large unmet need to understand which pregnancies are at-risk: unrecognized fetal growth restriction is the single largest risk factor for stillbirth and approximately 70% of babies with severe growth restriction are missed by a standard ultrasound. The Mirvie RNA platform has uncovered a unique molecular signature predictive for babies born with severe growth restriction, predicting 60% of babies born with the condition - months in advance of delivery, a significant improvement over the current standard of care. The #research also found current clinical risk factors used today, like advanced maternal age, maternal height, smoking status, and obesity are not predictive. This new scientific breakthrough adds to the growing body of research on the power of the Mirvie RNA platform to predict several dangerous pregnancy complications months before symptoms appear, including #preeclampsia risk prediction in Nature Magazine and preterm birth risk prediction in the American Journal of Obstetrics and Gynecology. Why is this important for patients? 🍼 The Mirvie RNA platform is unlocking the biology of #pregnancy and identifying which women are at the highest risk for serious complications, finally. This opens up the possibility of prevention - prevention of disease, prevention of near-death experiences, prevention of long NICU stays, and prevention of trauma. What does this mean for clinicians? 🥼 With the Mirvie RNA Platform, #physicians and care teams can move away from generalized risk factors like maternal characteristics and demographics and move toward a personalized care approach for the right patients at the right time, creating better outcomes for mom and baby. We’re excited to pioneer this research, unlocking the underlying biology of pregnancy health to create healthier futures for families. Read more in our press release: https://lnkd.in/gpcVFbij

AI is revolutionizing drug discovery. We can sift through vast databases to identify potential drug targets, predict drug-protein interactions, and design new molecules. This is why I was so excited to speak to Jim Tananbaum of Foresite Capital.   In the episode, we discuss: 1. The creation of GelTex Pharmaceuticals (ultimately acquired for $1.6 billion) while Jim was still in business school. 2. The complexity and economics of getting a drug company off the ground today. 3. New frontiers in cancer, obesity, and pain research. 4. How to run down the most promising molecules by sifting through a world of data. Jim is a vertiable encyclopedia and a pleasure to talk to. He can assuredly explain the most complex ideas in the field and give great insights into where we are headed. LISTEN HERE: https://lnkd.in/edQ6tKve Circulus Substack: https://lnkd.in/eaTdfyDT Tom Burroughes Stephen Harris Theodora Viney Samantha Norquist Philippa Ushio Nadia Damouni Rianna Bresse Hadi Tabbaa Cindy Lundin Mesaros Dennis Ryan Michael Rome Dorothy Margolskee Shannon Bergstedt Anthony Wiemelt, Ph.D. Vik Bajaj Jamie McLaughlin Steve Prostano Jacqueline Guttman Joshua Ben Rosen Nicholas Kyriacou Frazer Rice Brian C. Adams Kathy Sutherland

Exciting news for Spear Bio! We are dedicated to our mission of revolutionizing #biomarker #research and #diagnostics through #innovation and accessibility. Learn more: https://lnkd.in/eTVW8vAy #ENDALZ #Alzheimer’s #neurology #precisionmedicine #neuroscience #healthcareinnovation #healthtech

Foresight is thrilled to share that #ctDNA #MRD testing is now included in National Comprehensive Cancer Network® (NCCN®) Guidelines for #DLBCL – a first for this indication. The guidelines now recommend ctDNA-MRD testing to evaluate PET positive results at end of first-line DLBCL therapy.    "Until now, management of patients with a positive or equivocal PET scan at the end of therapy has been a challenging issue, particularly when biopsy is not possible. Furthermore, PET scans have a false positive rate, where 50% of positive scans or more are not due to residual lymphoma,” said Dr. Mark Roschewski from National Cancer Institute (NCI). “The inclusion of ctDNA testing in the NCCN Guidelines gives us a powerful tool to address both challenges – providing guidance when biopsy isn't possible and helping us more accurately determine which patients truly need additional therapy." This update follows Foresight's submission of clinical recommendations to the NCCN in August 2024 for the inclusion of ctDNA testing in guidelines, utilizing evidence generated by Foresight CLARITY™. Read our press release for more information - https://t.ly/Vwr_W

Sollis Health has closed $33M in Series B funding led by Foresite Capital. This milestone accelerates our mission to redefine healthcare with a seamless, patient-first approach by supporting the expansion of our signature concierge care into new markets. As seen this morning in Crain's New York Business, read the full announcement here: https://bit.ly/49kyZQ9